Resmed (RMD) EBIAT (2009 - 2026)

Resmed (RMD) has 18 years of EBIAT data on file, last reported at $398.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 9.23% year-over-year to $398.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 15.71% YoY), and the FY2025 full-year result was $1.4 billion, up 37.2% from the prior year.
• EBIAT for Q1 2026 stood at $398.7 million, up from $392.6 million in the prior quarter.
• Across five years, EBIAT topped out at $398.7 million in Q1 2026 and bottomed at $179.0 million in Q1 2022.
• The 5-year median for EBIAT is $292.2 million (2024), against an average of $284.3 million.
• The widest annual swing landed in 2022, when EBIAT jumped 328.1%; it then slipped 7.16% in 2023.
• A 5-year view of EBIAT shows it stood at $224.9 million in 2022, then declined by 7.16% to $208.8 million in 2023, then jumped by 65.05% to $344.6 million in 2024, then rose by 13.92% to $392.6 million in 2025, then climbed by 1.56% to $398.7 million in 2026.
• The last three EBIAT figures came in at $398.7 million (Q1 2026), $392.6 million (Q4 2025), and $348.5 million (Q3 2025), per Business Quant data.

Peer Comparison